ABVC BIOPHARMA, INC.
ABVC · XNASCIK 1173313fmd_0RP9GZCNMQ924PCZZ657YRST0VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2009 to Sep 30, 2026, 69 periods
| Line item | FY2017 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 |
| Cost of revenue | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Gross profit | – | – | (0) | 1 | 0 | 0 | 1 | (0) | 1 | – |
| Realized investment gains (losses) | – | – | 0 | – | (0) | – | (0) | (0) | (0) | (0) |
| Research and development | 3 | – | 1 | 1 | 1 | 1 | 3 | 1 | 0 | 0 |
| Selling, general and administrative | 1 | – | 2 | 3 | 4 | 6 | 6 | 5 | 2 | 3 |
| Total operating expenses | – | 4 | 3 | 4 | 9 | 12 | 16 | 7 | 5 | 7 |
| Operating income | (4) | – | (3) | (3) | (9) | (12) | (15) | (7) | (5) | (7) |
| Interest expense | 0 | – | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Interest and investment income | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | – | (4) | (1) | (2) | 0 | (0) | (1) | (1) | (1) |
| Income before taxes | (4) | – | (6) | (4) | (11) | (11) | (16) | (8) | (5) | (8) |
| Income tax expense | 0 | – | (0) | (0) | (0) | 1 | 1 | 0 | (0) | 0 |
| Net income from continuing operations | (4) | – | (6) | (4) | (11) | (12) | (16) | (8) | (5) | (8) |
| Net income | (4) | – | (6) | (4) | (11) | (13) | (16) | (8) | (5) | (8) |
| Net income to common shareholders | – | – | – | – | (10) | (13) | (16) | – | 5 | – |